| | | |
TABLE OF CONTENTS
| | | | Volume 7, July 2017 | | In this issue Original Articles Letters to the Editor | | | | | | | Original Articles | Top | | Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemiaH-A Hou, J-W Lu, T-Y Lin, C-H Tsai, W-C Chou, C-C Lin, Y-Y Kuo, C-Y Liu, M-H Tseng, Y-C Chiang, Y-L Peng, J-L Tang, Z Gong, L-I Lin and H-F Tien Blood Cancer J 2017 7: e588; 10.1038/bcj.2017.67 Abstract | Full Text | | | | Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cellsN Shenoy, T Bhagat, E Nieves, M Stenson, J Lawson, G S Choudhary, T Habermann, G Nowakowski, R Singh, X Wu, A Verma and T E Witzig Blood Cancer J 2017 7: e587; 10.1038/bcj.2017.65 Abstract | Full Text | | | | MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphomaJ Xiong, L Wang, X-C Fei, X-F Jiang, Z Zheng, Y Zhao, C-F Wang, B Li, S-J Chen, A Janin, R P Gale and W-L Zhao Blood Cancer J 2017 7: e582; 10.1038/bcj.2017.61 Abstract | Full Text | | Letters to the Editor | Top | | The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathwaysL Besse, M Kraus, A Besse, J Bader, T Silzle, T Mehrling and C Driessen Blood Cancer J 2017 7: e589; 10.1038/bcj.2017.69 Full Text | | | | Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemiaZ Gong, L J Medeiros, J E Cortes, L Zheng, J D Khoury, W Wang, G Tang, S Loghavi, R Luthra, W Yang, H M Kantarjian and S Hu Blood Cancer J 2017 7: e583; 10.1038/bcj.2017.62 Full Text | | | | Malignant T cells activate endothelial cells via IL-17 FB Lauenborg, I V Litvinov, Y Zhou, A Willerslev-Olsen, C M Bonefeld, C Nastasi, S Fredholm, L M Lindahl, D Sasseville, C Geisler, M M Wasik, T Krejsgaard, L M R Gjerdrum, L Iversen, N Odum and A Woetmann Blood Cancer J 2017 7: e586; 10.1038/bcj.2017.64 Full Text | | | | Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosisM M Patnaik, M M Timm, R Vallapureddy, T L Lasho, R P Ketterling, N Gangat, M Shi, A Tefferi, E Solary, K K Reichard and D Jevremovic Blood Cancer J 2017 7: e584;; 10.1038/bcj.2017.66 Full Text | | | | MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemiaK Vargova, M Pesta, P Obrtlikova, N Dusilkova, L Minarik, J Vargova, A Berkova, Z Zemanova, K Michalova, M Spacek, M Trneny and T Stopka Blood Cancer J 2017 7: e585; 10.1038/bcj.2017.63 Full Text | | | | | | | | You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. | | | | |
No comments:
Post a Comment